The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugs

Basit Öğe Kaydı
dc.authorwosidCakir, Necati/AAG-7283-2019
dc.contributor.authorPamuk, ÖN
dc.contributor.authorÇakir, N
dc.date.accessioned2024-06-12T10:55:59Z
dc.date.available2024-06-12T10:55:59Z
dc.date.issued2006
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: We aimed to evaluate the effect on renal functions and blood pressure of the addition of low dose aspirin (LDA) to cyclooxygenase-2 (COX-2) inhibitors or nonselective NSAIDs. Methods: Two groups each containing 14 patients with one group using celecoxib and the other indomethacin regularly for at least 1 week were included into the study. Both groups were initially administered 100 mg/day (week 1), and later 300 mg/day (week 2) aspirin. Baseline and weekly serum creatinine, uric acid, electrolytes, creatinine clearance (CrCl) and blood pressure were obtained. Results: Contrary to the celecoxib group, in the indomethacin group, both after the first and the second weeks the mean serum creatinine increased and CrCl decreased when compared to baseline values (p values < 0.05). In the indomethacin group, when compared to baseline values systolic blood pressure was significantly higher after week 1 and uric acid level after week 2 (p values=0.01). The frequency of patients with a >= 20% decrease in CrCl at the end of week 2 was higher in the indomethacin group than in the celecoxib group (42.9% vs. 0%, p=0.016). The difference between the mean creatinine (p=0.017) and CrCl values (p=0.007) from baseline until after week 2 was more significant in the indomethacin group than in the celecoxib group. Conclusions: The addition of LDA to patients using indomethacin led to significant renal dysfunction. Subjects using celecoxib seem to have been protected from the renal side effects of LDA.en_US
dc.identifier.doi10.1007/s10067-005-1167-9
dc.identifier.endpage125en_US
dc.identifier.issn0770-3198
dc.identifier.issn1434-9949
dc.identifier.issue1en_US
dc.identifier.pmid16175430en_US
dc.identifier.scopus2-s2.0-33645746513en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage123en_US
dc.identifier.urihttps://doi.org/10.1007/s10067-005-1167-9
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19630
dc.identifier.volume25en_US
dc.identifier.wosWOS:000233787500030en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofClinical Rheumatologyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCelecoxiben_US
dc.subjectCreatinine Clearanceen_US
dc.subjectLow Dose Aspirin (LDA)en_US
dc.subjectNon-Steroidal Antiinflammatory Drugs (Nsaids)en_US
dc.subjectSelective Cyclooxygenase-2 (COX-2) Inhibitorsen_US
dc.subjectCelecoxiben_US
dc.titleThe renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugsen_US
dc.typeLetteren_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu